Deploying Nu.Q® Capture as the first blood sample
processing step could potentially:
-
Enhance the sensitivity of subsequent Nu.Q® immunoassays for diagnosing and monitoring different types of disease using our proprietary Nucleosomics™ platform.
Aid the development of improved diagnostic DNA sequencing methods.
-
Serve as a quality control tool to reduce the rate of clinical test failure, saving time that is especially valuable for people whose test results are being used to inform their treatment.
-
Aid the discovery of new biomarkers.